Yuyu Pharma Inc

Yuyu Pharma Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.22, indicating limited leverage. The company's liquidity position is strong, with a current ratio of 1.64 and cash and equivalents amounting to KRW 29,090,832,980. The price-to-book ratio of 0.5 suggests the company is trading at a discount to its book value, while the price-to-tangible-book ratio of 0.5 reinforces this valuation signal. Profitability metrics show a return on equity of 6.29% and a return on assets of 3.93%, which are below the industry median for pharmaceutical firms. The gross margin of 38.3% (calculated from gross profit of KRW 53,941,098,760 and revenue of KRW 140,884,666,970) is in line with industry norms, but the operating margin of 7.1% (calculated from operating income of KRW 9,987,256,740) is below the median for the sector. The company's revenue is distributed across four segments: Yuyu Pharmaceutical, Yuyu Healthcare, Yuyu Medicals, and Yuyu Healthy Life. While the input data does not specify the exact revenue contribution of each segment, the company operates in both domestic and international markets. The geographic exposure is not quantified in the input data, but the presence of overseas sales suggests some diversification. Yuyu Pharma Inc reported revenue of KRW 140,884,666,970 in the latest period, with a price-to-earnings ratio of 8.0 and a price-to-revenue ratio of 0.45. Analysts recorded a last actual revenue of KRW 98,120,000,000, suggesting a recent growth trajectory. The company's capital expenditure of KRW -8,453,994,830 indicates a net cash inflow from investing activities, which may reflect asset sales or reduced capital spending. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position support the low liquidity risk rating. The absence of dilution risk is reinforced by the equality of basic and diluted shares outstanding (15,747,462 shares). Recent financial filings and transcripts do not highlight any material events or strategic shifts. The company's financial performance appears stable, with no significant changes in its business model or market position reported in the latest disclosures.